Save

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

PHASE2RECRUITING

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Simpliy with AI

Study details:

This is a phase 2, multicenter study to assess the safety, tolerability, CNS effects, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult participants with mild-to-moderate AD. The study will consist of 2 parts:. Part A: Placebo-controlled, randomized, safety and preliminary efficacy cohort with daily dosing for 28 day cycles.

Part B: a randomized expansion cohort of daily dosing for 28 day cycles.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Age 45-85

Diagnosis of mild to moderate AD

Clinical laboratory values within normal range or < 1.5 times ULN

If receiving AD-specific treatment, have been on stable dose for ≥ 3 months prior to first dose of study drug.

Life expectancy of >2 years

Able and willing to provide written informed consent

Exclusion criteria

Any physical or psychological condition that prohibits study completion

Known cardiac disease

Active or history of malignancy in the past 5 years

Serious infection that will not be resolved by first day of study intervention.

History of clinically significant CNS event or diagnosis in the past 5 years.

Acute illness within 30 days of Day 1

History of suicidal behavior or suicidal ideation

History of chronic alcohol use or substance abuse in the last 5 years

HIV, hepatitis B and/or hepatitis C positive

Vaccines within 14 days

Receipt of investigational products within 30 days

Blood donation within 30 days

Pregnant or breastfeeding

Simplify with AI

Eligibility

Age eligible for study : 45 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-07-29

Primary completion: 2025-12-01

Study completion finish: 2026-06-01

Study type

TREATMENT

Phase

PHASE2

Trial ID

NCT06427668

Intervention or treatment

DRUG: SPG302

DRUG: Placebo

Conditions

• Alzheimer Disease

Condition: Alzheimer Disease
DRUG: SPG302 and other drugs
Sydney, New South Wales, Australia and more
Sponsor: Spinogenix

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

St Vincent's Hospital

Research sites nearby

Select from list below to view details:

St Vincent's Hospital
Sydney, New South Wales, Australia
Flinders Medical center
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
ACTIVE_COMPARATOR: Part A: Active SPG302 to be administered to adult participants with AD Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be 300 mg orally once daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to cohort 2: 12 additional participants pending review of data, for additional dose exploration.	DRUG: SPG302 synthetic small molecule
PLACEBO_COMPARATOR: Part A: Placebo comparator to be administered to adult participants with AD Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be placebo capsule orally daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to 12 additional participants as cohort 2 pending review of data, for additional dose exploration.	DRUG: Placebo Placebo
EXPERIMENTAL: Part B: Expansion Cohort Dose to be used and size of dosing cohort to be determined by Data Safety and Monitoring Committee following completion of Part A.	DRUG: SPG302 synthetic small molecule

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Change in Electroencephalogram (EEG) at resting state and at auditory evoked P300 from baseline to endpoint	Electroencephalogram (EEG) will provide non-invasive measurement of brain activity. This test will be used to measure resting state cognitive activity as well as cognitive activity after auditory stimulation. Sound stimuli is 500Hz and 2000Hz.	8 months
Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpoint	The Alzheimer's Disease Assessment Scale-Cognitive Subscale test (ADAS-Cog) measures language and memory, focusing on cognitive and non-cognitive functioning. It evaluates word recall, naming of objects, word recognition, comprehension and word finding. The ADAS-COG is scored 0-70. The higher the score the greater the impairment.	8 months
Change in Mini-Mental State Examination (MMSE) from baseline to endpoint	The Mini-Mental State Exam (MMSE) is a test of cognitive function. It includes tests of orientation, attention, memory, language and visual-spatial skills. The lower the score the greater the impairment.	8 months
C-SSRS (Columbia Suicide Severity Rating Scale)	Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. The suicidal behavior lethality sub-scale inquires about the level of actual or potential medical damage.	8 months
Change in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) from baseline to endpoint	The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) is a metric for clinical assessment of symptom severity. It consists of 2 parts. First a baseline evaluation of patient and caregiver is performed to collect necessary clinical information. The clinician will then conduct the second phase of the assessment after a specified time period, and changes in symptom severity are indicated on a seven point scale. A higher scale indicates a worsening of symptoms.	8 months
Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale from baseline to endpoint	The Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale is an scale that assesses the performance of daily tasks and activities. A lower score indicates lower functional performance.	8 months
Quality of Life in Alzheimer's Disease (QOL-AD) from baseline to endpoint	The Quality of Life in Alzheimer's Disease (QOL-AD) is a test to evaluate the quality of life through a series of questions of ability to complete daily activities and tasks. A lower score indicates lower functional quality of life.	8 months

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Safety and tolerability of SPG302	Incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs)	8 months
Plasma pharmacokinetics of SPG302 in participants with AD-Maximum Plasma Concentration (Cmax)	Blood will be collected following administration of SPG302 and plasma levels will be evaluated to measure the maximum concentration.	8 months
Change in biomarkers in participants with AD from baseline to endpoint.	To assess the effect of SPG302 on Neurofilament light (NfL), a protein elevated in AD. This will be measured in picometers/milliliter.	8 months

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)